EUCTR2012-002792-34-GB
Active, not recruiting
Phase 1
Phenotyping bronchiectasis based on aetiology, exacerbation characteristics and response to erythromycin. - Phenotyping bronchiectasis over 2 years including a macrolide trial
niversity Hospitals Leicester NHS Trust0 sites90 target enrollmentMarch 13, 2014
ConditionsBronchiectasisMedDRA version: 16.1Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
DrugsErythromycin
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Bronchiectasis
- Sponsor
- niversity Hospitals Leicester NHS Trust
- Enrollment
- 90
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Group 1 \- 40 participants over 2 years including the intervention
- •\- Patients who have clinical symptoms suggestive of bronchiectasis confirmed by CT scan.
- •\- Aged 18\-100\.
- •\- Ability to give valid consent.
- •\- Willingness to attend the hospital every 3 months for 2 years.
- •Group 2 \- 50 participants for baseline visit only
- •\- Patients who have clinical symptoms suggestive of bronchiectasis confirmed by CT scan.
- •\- Aged 18\-100\.
- •\- Ability to give valid consent.
- •\- Willingness to attend the hospital for a one off visit.
Exclusion Criteria
- •Group 1 \- 40 participants over 2 years including the intervention
- •\- Active TB.
- •\- Patients under 18 and over 100\.
- •\- Patients who are too unwell to attend visits.
- •\- Patients with known cystic fibrosis.
- •\- Patients with traction bronchiectasis secondary to fibrosis.
- •\- Patients who are unable to consent.
- •\- Patients already on long term antibiotics.
- •\- Patients with macrolide allergy / severe intolerance / prolonged QT interval.
- •\- Patients taking medication with a known interaction with erythromycin where the use is contraindicated, with the exception of simvastatin.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Not Applicable
Role of Bronchoscopy in BronchiectasisBronchoscopyNCT04208607Assiut University60
Terminated
Phase 4
The prevention of airway narrowing following dry powder mannitol inhalation in susceptible bronchiectatic patientsPrevention of airway narrowing in bronchiectatic patients following inhalation of dry powder mannitolRespiratory - AsthmaACTRN12607000379415Sydney South West Area Health Service25
Terminated
Not Applicable
Different Phenotypes of BronchiectasisBronchiectasisNCT03262064Assiut University100
Completed
Not Applicable
Cross-sectional Characterization of Idiopathic BronchiectasisInfectionBronchial DiseasesRespiratory Tract DiseasesNCT01264055National Heart, Lung, and Blood Institute (NHLBI)275
Unknown
Not Applicable
Prevalence of Bronchiectasis in COPD PatientsBronchiectasisChronic Obstruct Airways DiseasePrognosisNCT04101448Assiut University100